Informations générales (source: ClinicalTrials.gov)
Circulating " Cancer Cells / Macrophage " HYbrid Cells in Patients With Sarcoma, Part 2
Interventional
N/A
Institut Claudius Regaud (Voir sur ClinicalTrials)
janvier 2023
juillet 2026
13 septembre 2025
Pilot, prospective, monocentric study aimed at evaluating the rate of patients with
circulating "cancer cell/macrophage" hybrid cells in the peripheral blood and the
evolution of this rate over time.
The study will be conducted on a population of patients with leiomyosarcoma and treated
in the context of routine care. 20 patients will be included:
- 10 patients with localized disease.
- 10 patients with metastatic disease.
For each included patient, blood samples will be collected during baseline visit and up
to 24 months after inclusion.
Etablissements
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Institut Universitaire du Cancer Toulouse - Oncopole - 31059 - Toulouse - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
Inclusion Criteria:
1. Patient with leiomyosarcoma.
2. Diagnosis of sarcoma histologically confirmed by the RRePS network (Réseau de
Référence en Pathologie des Sarcomes et des Viscères)
3. Localized or metastatic disease
4. Newly diagnosed patient who has not yet initiated specific treatment for sarcoma
5. Age ≥ 18 years
6. Patient affiliated to a Social Security system in France.
7. Patient having signed informed consent prior to inclusion in the study and prior to
any specific study procedures
1. Patient with leiomyosarcoma.
2. Diagnosis of sarcoma histologically confirmed by the RRePS network (Réseau de
Référence en Pathologie des Sarcomes et des Viscères)
3. Localized or metastatic disease
4. Newly diagnosed patient who has not yet initiated specific treatment for sarcoma
5. Age ≥ 18 years
6. Patient affiliated to a Social Security system in France.
7. Patient having signed informed consent prior to inclusion in the study and prior to
any specific study procedures
1. Diagnosis of any other histological subtype of soft tissue sarcoma
2. Associated pathology(ies) that may interfere with the study procedure
3. Pregnant or breastfeeding woman
4. Any psychological, family, geographical or sociological condition that does not
allow for compliance with the medical follow-up and/or procedures provided for in
the study protocol.
5. Patient who has forfeited his/her freedom by administrative or legal award or who is
under legal protection (curatorship and guardianship, protection of justice).